AstraZeneca PLC (AZN) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin strength ⢠Cash flow ⢠Liquidity risk AZN delivered strong profitability, margins, and cash flow, but its case is tempered by tight liquidity, rising leverage, and a valuation that looks full.
Price Behavior
Key Price Behavior Insights: ⢠Recent rebound ⢠Lower highs/lows ⢠Range-bound action Support Level: $176-$177 Resistance Level: $187-$190 AZN is slightly higher over the last month but still choppy, with a rebound from the recent low offset by a short-term pattern of lower highs/lows and resistance at $187-$190.
Sentiment & News
Key News Insights: ⢠Oncology growth ⢠FDA approvals ⢠Valuation pressure AstraZeneca's headlines point to strong oncology-led growth, new approvals and pipeline progress, but regulatory delays, valuation worries, and mixed analyst sentiment temper the outlook.
AI Summary
AZN now looks more like a high-quality, cash-generative commercial pharma platform with pipeline upside than a pure pipeline bet, but at ~31x earnings the stock needs faster approval-to-uptake execution and continued margin expansion to avoid multiple compression, especially given weak near-term chart momentum and a stretched balance sheet.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |